Evolving therapeutic targets in ischemic stroke: A concise review

Current Drug Targets

Volumn 14, Issue 4, 2013, Pages 497-506

  Sugunan, Sinoy ^a   Joseph, Diya Binoy ^a   Rajanikant, G K ^a  

^a NATIONAL INSTITUTE OF TECHNOLOGY CALICUT   (India)

Author keywords

Excitotoxicity; Inflammation; Ischemic stroke; MHC I; NADPH oxidase; Neuroplasticity; Therapeutic targets

Indexed keywords

COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN NOGO A; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOPHOSPHORYLATION; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; BRAIN ISCHEMIA; DOUBLE STRANDED DNA BREAK; EXCITOTOXICITY; HUMAN; MORBIDITY; MORTALITY; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; OXIDATIVE STRESS; POSTSYNAPTIC DENSITY; PROTEIN PHOSPHORYLATION; SRC HOMOLOGY DOMAIN; VALIDATION PROCESS;

ANIMALS; BRAIN ISCHEMIA; HUMANS; MOLECULAR TARGETED THERAPY; PROTEINS; STROKE;

EID: 84876734742     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314040011     Document Type: Article

References (124)

1. Katsura K, Folbergrová J, Gidö G, Siesjö BK. Functional, metabolic, and circulatory changes associated with seizure activity in the post ischemic brain. J Neurochem 1994; 62: 1511-5.
2. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391-7.
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-7.
4. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002; 33: 2123-36.
5. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4: 399-415.
6. Ginsberg MD. Neuroprotection For Ischemic Stroke: Past, Present And Future. Neuropharmacology 2008; 55: 363-89.
7. Bennett KS, Morita DC. Drugs in pediatric ischemic stroke. Curr Drug Targets 2012; 13: 917-24.
8. Kelso ML, Oestreich JH. Traumatic brain injury: central and peripheral role of a7 nicotinic acetylcholine receptors. Curr Drug Targets 2012; 13: 631-6.
9. Ying W. New mechanisms of neuronal injury and neuroprotection. Curr Drug Targets 2012; 13: 157-8.
10. Ge P, Zhang F, Zhao J, Liu C, Sun L, Hu B. Protein degradation pathways after brain ischemia. Curr Drug Targets 2012; 13: 159-65.
11. Wang Y, Huang J, Li Y, Yang GY. Roles of chemokine CXCL12 and its receptors in ischemic stroke. Curr Drug Targets 2012; 13: 166-7.
12. Zhao H, Ren C, Chen X, Shen J. From rapid to delayed and remote postconditioning: the evolving concept of ischemic postconditioning in brain ischemia. Curr Drug Targets 2012; 13: 173-87.
13. Shao B, Cheng Y, Jing K. Estrogen, neuroprotection, neurogenesis after ischemic stroke. Curr Drug Targets 2012; 13: 188-98.
14. Cairns B, Kim JY, Tang XN, Yenari MA. NOX inhibitors as a therapeutic strategy for stroke and neurodegenerative disease. Curr Drug Targets 2012; 13: 199-206.
15. Mergenthaler P, Meisel A. Do stroke models model stroke? Dis Model Mech 2012; 5: 718-25.
16. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke Therapy Academic Industry Roundtable (STAIR). Stroke 1999; 30: 2752-8.
17. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004; 1: 36-45.
18. Macrae IM. Preclinical stroke research--advantages and disadvantages of the most common rodent models of focal ischaemia. Br J Pharmacol 2011; 164: 1062-78.
19. Liu S, Zhen G, Meloni BP, Campbell K, Winn HR. Rodent stroke model guidelines for preclinical stroke trials. J Exp Stroke Transl Med 2009; 2: 2-27.
20. Auriel E, Bornstein NM. Neuroprotection in acute ischemic stroke--current status. J Cell Mol Med 2010;14: 2200-2.
21. Christopherson KS, Hillier BJ, Lim WA, Bredt DS. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem 1999; 274: 27467-73.
22. Cui H, Hayashi A, Sun HS, et al. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci 2007; 27: 9901-15.
23. Blazer LL, Neubig RR. Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: Current progress and future hurdles. Neuropsychopharmacology 2009; 34: 126-41.
24. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 1991; 88: 6368-71.
25. Aarts M, Liu Y, Liu L, et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002; 298: 846-50.
26. Bråtane BT, Cui H, Cook DJ, et al. Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor. Stroke 2011; 42: 3265-70.
27. Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 2012; 483: 213-7.
28. Cook DJ, Teves L, Tymianski M. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci Transl Med 2012; 4: 154ra133.
29. Bach A, Eildal JN, Stuhr-Hansen N, et al. Cell-permeable and plasma-stable peptidomimetic inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem 2011; 54: 1333-46.
30. Bach A, Clausen BH, Møller M, et al. A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage. Proc Natl Acad Sci USA 2012; 109: 3317-22.
31. Zhou L, Li F, Xu HB, et al. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat Med 2010; 16: 1439-43.
32. Jones N. Stroke: Disruption of the nNOS-PSD-95 complex is neuroprotective in models of cerebral ischemia. Nat Rev Neurol 2011; 7: 61.
33. Yang ZJ, Carter EL, Torbey MT, Martin LJ, Koehler RC. Sigma receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine modulates neuronal nitric oxide synthase/postsynaptic density-95 coupling mechanisms and protects against neonatal ischemic degeneration of striatal neurons. Exp Neurol 2010; 221: 166-74.
34. Du CP, Gao J, Tai JM, et al. Increased tyrosine phosphorylation of PSD-95 by Src family kinases after brain ischaemia. Biochem J 2009; 417: 277-85.
35. Thorsen TS, Madsen KL, Rebola N, et al. Identification of a smallmolecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD. Proc Natl Acad Sci USA 2010; 107: 413-8.
36. Wang WW, Hu SQ, Li C, et al. Transduced PDZ1 domain of PSD-95 decreases Src phosphorylation and increases nNOS (Ser847) phosphorylation contributing to neuroprotection after cerebral ischemia. Brain Res 2010; 1328: 162-70.
37. Hu SQ, Zong YY, Fan LM, Zhang GY. Overexpression of PDZ1 domain prevents apoptosis of rat hippocampal neurons induced by kainic acid. Neurosci Lett 2009; 460: 133-7.
38. Hu SQ, Zhu J, Pei DS, et al. Overexpression of the PDZ1 domain of PSD-95 diminishes ischemic brain injury via inhibition of the GluR6. PSD-95. MLK3 pathway. J Neurosci Res 2009; 87: 3626-38.
39. Tabuchi K, Biederer T, Butz S, Sudhof TC. CASK participates in alternative tripartite complexes in which Mint 1 competes for bind ing with caskin 1, a novel CASK-binding protein. J Neurosci 2002; 22: 4264-73.
40. Balazs A, Csizmok V, Buday L, et al. High levels of structural disorder in scaffold proteins as exemplified by a novel neuronal protein, CASK-interactive protein1. FEBS J 2009; 276: 3744-56.
41. Datta A, Jingru Q, Khor TH, et al. Quantitative neuroproteomics of an in vivo rodent model of focal cerebral ischemia/reperfusion injury reveals a temporal regulation of novel pathophysiological molecular markers. J Proteome Res 2011; 10: 5199-13.
42. Boeckers TM, Kreutz MR, Winter C, et al. Proline-rich synapseassociated protein-1/cortactin binding protein 1 (Pro-SAP1/CortBP1) is a PDZ-domain protein highly enriched in the postsynaptic density. J Neurosci 1999; 19: 6506-18.
43. Petralia RS, Sans N, Wang YX, Wenthold RJ. Ontogeny of postsynaptic density proteins at glutamatergic synapses. Mol Cell Neurosci 2005; 29: 436-52.
44. Sala C, Piech V, Wilson NR, et al. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron 2001; 31: 115-30.
45. Boeckers TM, Liedtke T, Spilker C, et al. C-terminal synaptic targeting elements for postsynaptic density proteins Pro-SAP1/Shank2 and ProSAP2/Shank3. J Neurochem 2005; 92: 519-24.
46. Boeckers TM, Bockmann J, Kreutz MR, Gundelfinger ED. Pro-SAP/Shank proteins-a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. J Neurochem 2002; 81: 903-10.
47. Kim E, Sheng M. PDZ domain proteins of synapses. Nat Rev Neurosci 2004; 5: 771-81.
48. Rostaing P, Real E, Siksou L, et al. Analysis of synaptic ultrastructure without fixative using high-pressure freezing and tomography. Eur J Neurosci 2006; 24: 3463-74.
49. de Bartolomeis A, Tomasetti C. Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins. Mol Neurobiol 2012; 46: 275-96.
50. Farkas IJ, Szanto-Várnagy A, Korcsmaros T. Linking proteins to signaling pathways for experiment design and evaluation. PLoS One 2012; 7: e36202.
51. Brown DI, Griendling, KK. Nox proteins in signal transduction. Free Radic Biol Med 2009; 47: 1239-53.
52. Ambasta RK, Kumar P, Griendling KK, et al. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 2004; 279: 45935-41.
53. Crossley NA, Sena E, Goehler J, et al. Empirical evidence of bias in the design of experimental stroke studies: a meta epidemiologic approach. Stroke 2008; 39: 929-34.
54. Kleinschnitz C, Grund H, Wingler K, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biology 2010; 8: pii: e1000479.
55. Tang XN, Cairns B, Kim JY, Yenari MA. NADPH oxidase in stroke and cerebrovascular disease. Neurol Res 2012; 34: 338-45.
56. Kahles T, Brandes RP. NADPH oxidases as therapeutic targets in ischemic stroke. Cell Mol Life Sci 2012; 69: 2345-63.
57. Ramsey IS, Moran MM, Chong JA, Clapham DE. A voltage-gated proton-selective channel lacking the pore domain. Nature 2006; 440: 1213-16.
58. Murata Y, Iwasaki H, Sasaki M, Inaba K, Okamura Y. Phosphoinositide phosphatase activity coupled to an intrinsic voltage sensor. Nature 2005; 435: 1239-43.
59. Wu LJ, Wu G, Akhavan Sharif MR, et al. The voltage-gated proton channel Hv1 enhances brain damage from ischemic stroke. Nat Neurosci 2012; 15: 565-73.
60. Chen YJ, Raman G, Bodendiek S, O'Donnell ME, Wulff H. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab 2011; 31: 2363-74.
61. Kaushal V, Koeberle PD, Wang Y, Schlichter LC. The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. J Neurosci 2007; 27: 234-44.
62. Bouhy D, Ghasemlou N, Lively S, et al. Inhibition of the Caβ-dependent Kβ channel, KCNN4/KCa3.1, improves tissue protection and locomotor recovery after spinal cord injury. J Neurosci. 2011; 31: 16298-308.
63. Liu BS, Ferreira R, Lively S, Schlichter LC. Microglial SK3 and SK4 currents and activation state are modulated by the neuroprotective drug, Riluzole. J Neuroimmune Pharmacol 2012 [Epub ahead of print].
64. Corriveau RA, Huh GS, Shatz CJ. Regulation of class I MHCgene expression in the developing and mature CNS by neural activity. Neuron 1998; 21: 505-20.
65. Datwani A, McConnell MJ, Kanold PO, et al. Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity. Neuron 2009; 64: 463-70.
66. Huh GS, Boulanger LM, Du H, et al. Functional requirement for class I MHC in CNS development and plasticity. Science 2000; 290: 2155-59.
67. Shatz CJ. MHC class I: an unexpected role in neuronal plasticity. Neuron 2009; 64: 40-45.
68. Needleman LA, Liu XB, El-Sabeawy F, Jones EG, McAllister AK. MHC class I molecules are present both pre-and post synaptically in the visual cortex during postnatal development and in adulthood. Proc Natl Acad Sci USA 2010; 107: 16999-17004.
69. McConnell MJ, Huang YH, Datwani A, Shatz CJ. H2-K(b) and H2-D(b) regulate cerebellar long-term depression and limit motor learning. Proc Natl Acad Sci USA 2009; 106: 6784-89.
70. Matsushita H, Endo S, Kobayashi E, et al. Differential but competitive binding of Nogo protein and class i major histocompatibility complex (MHCI) to the PIR-B ectodomain provides an inhibition of cells. J Biol Chem 2011; 286: 25739-47.
71. Syken J, Grandpre T, Kanold PO, Shatz CJ. PirB restricts oculardominance plasticity in visual cortex. Science 2006; 313: 1795-1800.
72. Piehl F, LidmanO. Neuroinflammation in the rat-CNS cells and their role in the regulation of immune reactions. Immunol Rev 2001; 184: 212-25.
73. Thams S, Oliveira A, Cullheim S. MHC class I expression and synaptic plasticity after nerve lesion. Brain Res Rev 2008; 57: 265-69.
74. Adelson JD, Barreto GE, Xu L, et al. Neuroprotection from Stroke in the Absence of MHCI or PirB. Neuron 2012; 73: 1100-7.
75. Chuang DM, Hough C, Senatorov VV. Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. Annu Rev Pharmacol Toxicol 2005; 45: 269-90.
76. Hara MR, Cascio MB, Sawa A. GAPDH as a sensor of NO stress. Biochim Biophys Acta 2006; 1762: 502-509.
77. Sirover MA. New nuclear functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. J Cell Biochem 2005; 95: 45-52.
78. Benhar M, Stamler JS. A central role for S-nitrosylation in apoptosis. Nat Cell Biol 2005; 7: 645-46.
79. Hara MR, Agrawal N, Kim SF, et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat Cell Biol 2005; 7: 665-74.
80. Sen N, Hara MR, Kornberg MD, et al. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol 2008; 10: 866-73.
81. Sen N, Hara MR, Ahmad AS, et al. GOSPEL: A novel neuroprotective protein that binds to GAPDH upon S-nitrosylation. Neuron 2009; 63: 81-91.
82. Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelinassociated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000; 403: 434-39.
83. GrandPre T, Nakamura F, Vartanian T, Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000; 403: 439-44.
84. Spillmann AA, Bandtlow CE, Lottspeich F, Keller F, Schwab ME. Identification and characterization of a bovine neurite growth inhibitor (bNI-220). J Biol Chem 1998; 273: 19283-93.
85. Wang H, Yao Y, Jiang X, et al. Expression of Nogo-A and NgR in the developing rat brain after hypoxia-ischemia. Brain Res 2006; 1114: 212-20.
86. Huber AB, Weinmann O, Brosamle C, Oertle T, Schwab ME. Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. J Neurosci 2002; 22: 3553-67.
87. Peng X, Kim J, Zhou Z, Fink DJ, Mata M. Neuronal Nogo-A regulates glutamate receptor subunit expression in hippocampal neurons. J Neurochem 2011; 119: 1183-93.
88. Thallmair M, Metz GA, Z'Graggen WJ, et al. Neurite growth inhibitors restrict plasticity and functional recovery following corticospinal tract lesions. Nat Neurosci 1998; 1: 124-31.
89. Raineteau O, Fouad K, NothP, Thallmair M, Schwab ME. Functional switch between motor tracts in the presence of the mAb IN-1in the adult rat. Proc Natl Acad Sci USA 2001; 98: 6929-34.
90. Liebscher T, Schnell L, Schnell D, et al. Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. Ann Neurol 2005; 58: 706-19.
91. Freund P, Schmidlin E, Wannier T, et al. Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nat Med 2006; 12: 790-92.
92. Freund P, Schmidlin E, Wannier T, et al. Anti-Nogo-A antibody treatment promotes recovery of manual dexterity after unilateral cervical lesion in adult primates-re-examination and extension of behavioral data. Eur J Neurosci 2009; 29: 983-96.
93. Gonzenbach RR, Zoerner B, Schnell L, et al. Delayed anti-Nogo-A antibody application after spinal cord injury shows progressive loss of responsiveness. J Neurotrauma 2012; 29: 567-78.
94. Oertle T, Klinger M, Stuermer CA, Schwab ME. A reticular rhapsody: phylogenic evolution and nomenclature of the RTN/Nogogene family. FASEB J 2003; 17: 1238-47.
95. Niederost B, Oertle T, Fritsche J, McKinney RA, Bandtlow CE. Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation of RhoA and Rac1. J Neurosci 2002; 22: 10368-76.
96. Sarkey JP, Chu M, McShane M, et al. Nogo-A knockdown inhibits hypoxia/reoxygenation-induced activation of mitochondrialdependent apoptosis in cardiomyocytes. J Mol Cell Cardiol 2011; 50: 1044-55.
97. Cheatwood JL, EmerickAJ, Schwab ME, Kartje GL. Nogo-A expression after focal ischemic stroke in the adult rat. Stroke 2008; 39: 2091-98.
98. Kilic E, ElAli A, Kilic U, et al. Role of Nogo-A in neuronal survival in the reperfused ischemic brain. J Cereb Blood Flow Metab 2010; 30: 969-84.
99. Zhu WW, Ma XL, Guo AL, Zhao HY, Luo HH. Neuroprotective effects of NEP1-40 and fasudil on Nogo-A expression in neonatal rats with hypoxic-ischemic brain damage. Genet Mol Res 2011; 10: 2987-95.
100. Gou X, Wang Q, Yang Q, Xu L, Xiong L. TAT-NEP1-40 as a novel therapeutic candidate for axonal regeneration and functional recovery after stroke. J Drug Target 2011; 19: 86-95.
101. Dizdaroglu M. Substrate specificities and excision kinetics of DNA glycosylases involved in base-excision repair of oxidative DNA damage. Mutat Res 2003; 531: 109-26.
102. Hamilton ML, Van RH, Drake JA, et al. Does oxidative damage to DNA increase with age? Proc Natl Acad Sci USA 2001; 98: 10469-74.
103. Barja G. Free radicals and aging. Trends Neurosci 2004; 27: 595-600.
104. Nakabeppu Y, Tsuchimoto D, Ichinoe A, et al. Biological significance of the defense mechanisms against oxidative damage in nucleic acids caused by reactive oxygen species: from mitochondria to nuclei. Ann NY Acad Sci 2004; 1011: 101-11.
105. Li W, Luo Y, Zhang F, et al. Ischemic preconditioning in the rat brain enhances the repair of endogenous oxidative DNA damage by activating the base-excision repair pathway. J Cereb Blood Flow Metab 2006; 26: 181-98.
106. Liu D, Smith CL, Barone FC, et al. Astrocytic demise precedes delayed neuronal death in focal ischemic rat brain. Brain Res Mol Brain Res 1999; 68: 29-41.
107. Lan J, Li W, Zhang F, et al. Inducible repair of oxidative DNA lesions in the rat brain after transient focal ischemia and reperfusion J Cereb Blood Flow Metab 2003; 23: 1324-39.
108. Liu D, Croteau DL, Souza-Pinto N, et al. Evidence that OGG1 glycosylase protects neurons against oxidative DNA damage and cell death under ischemic conditions. J Cereb Blood Flow Metab 2011; 31: 680-92.
109. Wang W, Esbensen Y, Kunke D, et al. Mitochondrial DNA damage level determines neural stem cell differentiation fate. J Neurosci 201; 31: 9746-51.
110. Goshima Y, Nakamura F, Strittmatter P, Strittmatter SM. Collapsin induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature 1995; 376: 509-14.
111. Minturn JE, Fryer HJ, Geschwind DH, Hockfield S. TOAD-64, a gene expressed early in neuronal differentiation in the rat, is related to unc-33, a C. Elegans gene involved in axon outgrowth. J Neurosci 1995; 15: 6757-66.
112. Byk T, Dobransky T, Cifuentes-Diaz C, Sobel A. Identification and molecular characterization of Unc-33-like phosphoprotein (Ulip), a putative mammalian homolog of the axonal guidanceassociated unc-33 gene product. J Neurosci 1996; 16: 688-701.
113. Gaetano C, Matsuo T, Thiele CJ. Identification and characterization of a retinoic acid-regulated human homologue of the unc-33-like phosphoprotein gene (hUlip) from neuroblastoma cells. J Biol Chem 1997; 272: 12195-201.
114. Inatome R, Tsujimura T, Hitomi T, et al. Identification of CRAM, a novel unc-33gene family protein that associates with CRMP3 and protein-tyrosine kinase(s) in the developing rat brain. J Biol Chem 2000; 275: 27291-302.
115. Yuasa-Kawada J, Suzuki R, Kano F, et al. Axonal morphogenesis controlled by antagonistic roles of two CRMPsubtypes in microtubule organization. Eur J Neurosci 2003; 17: 2329-43.
116. Suzuki Y, Nakagomi S, Namikawa K, et al. Collapsin response mediator protein-2 accelerates axon regeneration of nerve-injured motor neurons of rat. J Neurochem 2003; 86: 1042-50.
117. Alabed YZ. Identification of CRMP4 as a convergent regulator of axon outgrowth inhibition. J Neurosci 2007; 27: 1702-11.
118. Tanaka H, Morimura R, Ohshima T. Dpysl2 (CRMP2) and Dpysl3 (CRMP4) phosphorylation by Cdk5 and DYRK2 is required for proper positioning of Rohon-Beard neurons and neural crest cells during neurulation in zebrafish. Dev Biol. 2012; 370: 223-36.
119. Yan Q, Radeke MJ, Matheson CR, et al. Immunocytochemical localization of TrkB in the central nervous system of the adult rat. J Comp Neurol 1997; 378: 1351-57.
120. Kaplan DR, Atwal JK, Massie B, Miller FD. The TrkB-Shc Site Signals Neuronal Survival and Local Axon Growth via MEK and PI3-Kinase. Neuron 2000; 27: 265-77.
121. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003; 72: 609-42.
122. O'Leary PD, Hughes RA. Design of potent peptide mimetics of brain-derived neurotrophic factor. J Biol Chem 2003; 278: 25738-44.
123. Liu X, Chan CB, Qi Q. Optimization of a small Tropomyosin-Related Kinase B (TrkB) agonist 7,8-Dihydroxyflavone active in mouse models of depression. J Med Chem 2012; 55: 8524-37.
124. Qian MD, Zhang J, Tan XY, et al. Novel agonist monoclonal antibodies activate TrkB receptors and demonstrate potent neurotrophic activities. J Neurosci 2006; 27: 9394-403.